CNBX (CNBX Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Nov. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CNBX Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Nov. 2024 was 0.00.

CNBX Pharmaceuticals's long-term debt to total assets ratio stayed the same from Nov. 2023 (0.00) to Nov. 2024 (0.00).

CNBX Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for CNBX Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals LT-Debt-to-Total-Asset Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

CNBX Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

CNBX Pharmaceuticals LT-Debt-to-Total-Asset Calculation

CNBX Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as

LT Debt to Total Assets (A: Aug. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Aug. 2024 )	/	Total Assets (A: Aug. 2024 )
	=	0	/	0.031
	=	0.00

CNBX Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Nov. 2024 is calculated as

LT Debt to Total Assets (Q: Nov. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Nov. 2024 )	/	Total Assets (Q: Nov. 2024 )
	=	0	/	0.022
	=

CNBX Pharmaceuticals (OTCPK:CNBX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CNBX Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary